scholarly journals Six-month outcomes of an integrated primary care prevention and management program  for chronic low back pain (LBP) 

Author(s):  
Sara Ahmed ◽  
Regina Visca ◽  
Amede Gogovor ◽  
Owis Eilayyan ◽  
Roderick Finlayson ◽  
...  

Abstract Background Accessible interdisciplinary, patient-centered and integrated primary care programs for chronic pain are needed for averting chronicity and improving patient outcomes. We sought 1) to develop an interdisciplinary low back pain (LBP) primary care program, and 2) to evaluate the program’s implementation and impact on patients’ physical and mental health over 6 months. A quasi-experimental pre-test/post-test design was used, and participants completed baseline, 3 and 6 months post-intervention evaluations. Referral and program process indicators were measured. Methods Clinically meaningful change in patient reported outcome measures of pain interference and intensity, physical function, depression and anxiety were defined a priori and evaluated. A multilevel regression analysis was performed to evaluate the impact of the program on change in individuals’ pain interference over 6 months. Results Forty six percent of participants were seen within 60 days of referral to the LBP program, and 464 individuals completed the program. The majority (≥ 60%) experienced a clinically meaningful improvement for pain intensity and interference at six months. A greater proportion of those with moderate (71%) or high risk (81%) of chronicity showed an improvement in pain interference than those with low risk (51%). A similar pattern emerged for depression and self-efficacy, but not for anxiety. Significant predictors of improvements in pain interference included higher prognostic risk of chronicity, younger age, sex, and lower baseline disability. Conclusion Results supported an improvement in participants’ confidence to manage their LBP. Future research will compare alternative modes of delivery (e.g. telehealth) and stratification approaches to further tailor resources to individuals’ needs.

2008 ◽  
Vol 12 (2) ◽  
pp. 180-188 ◽  
Author(s):  
Gwenllian Wynne-Jones ◽  
Kate M. Dunn ◽  
Chris J. Main

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e027745 ◽  
Author(s):  
Timothy David Noblet ◽  
John F Marriott ◽  
Alison B Rushton

IntroductionLow back pain (LBP) is the most prevalent musculoskeletal condition in the UK. Guidelines advocate a multimodal approach, including prescription of medications. Advanced physiotherapy practitioners (APPs) are well placed to provide this care in primary care. Physiotherapist independent prescribing remains novel, with the first prescribers qualifying in 2014. This feasibility trial aims to evaluate the feasibility, suitability and acceptability of assessing the effectiveness of independent prescribing by APPs for patients with LBP in primary care, to inform the design of a future definitive stepped-wedged cluster trial.Method and analysis(1) Trial component. An APP (registered prescriber) will complete the initial participant consultation. If prescription drugs are required within the multimodal physiotherapeutic context, these will be prescribed. Patient-reported outcome measures will be completed prior to initial assessment and at 6 and 12 weeks to assess feasibility of follow-up and data collection procedures. Accelerometers will be fitted for 7 days to assess physical activity, sedentary behaviour and feasibility of use. (2) Embedded qualitative component. A focus group and semistructured interviews will be used to evaluate the views and experiences of the participants and APPs respectively, about the feasibility, suitability and acceptability of the proposed full trial. A Consolidated Standards of Reporting Trials diagram will be used to analyse feasible eligibility, recruitment and follow-up rates. Descriptive analysis of the data will be completed to evaluate procedures. Thematic analysis will be used to analyse and synthesise the qualitative data.Ethics and disseminationThis feasibility trial is approved by the Health Research Authority (HRA). Ethical approval was sought and granted via the Integrated Research Application System (IRAS) ID 250734.Data will be disseminated via publication in peer reviewed journal and conference presentation. It is anticipated that the results of this study will be used in conjunction with ethical evaluation, economic and risk analyses, as well as consultation with key stakeholders including the British health consumer when contemplating change, enhancement or redesign of the essential full randomised controlled trial.Trial registration numberISRCTN15516596, Pre-results.


2008 ◽  
Vol 12 (3) ◽  
pp. 275-283 ◽  
Author(s):  
Jean-François Chenot ◽  
Corinna Leonhardt ◽  
Stefan Keller ◽  
Martin Scherer ◽  
Norbert Donner-Banzhoff ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document